Cancer clinical trials in the region Île-de-France
684 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Lung cancer
#NCT04585750
#2023-504251-27-00
Phase 2 cohorte de patients atteints de cancer du poumon
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
KRAS G12C
KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Breast cancer
#NCT04585750
#2023-504251-27-00
Phase 2 cohorte de cancer du sein
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
KRAS G12C
KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Endometrial cancer
#NCT04585750
#2023-504251-27-00
Phase 2 cohorte de patients atteints d'un cancer de l'endomètre
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
KRAS G12C
KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Lung cancer
Colon cancer
Rectal cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Cervical / Vulvar / Vaginal cancer
#NCT07169734
#2025-521441-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Cervical cancer
Required histologic sub types
Squamous NSCLC
Adenocarcinoma
Intrahepatic cholangiocarcinoma
Urothelial carcinoma
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
4 recruiting sites
Alentis Therapeutics AG
Phase 1 / Phase 2
Lung cancer
Colon cancer
Rectal cancer
Stomach and esophageal cancer
Head and neck cancer
#NCT07151040
#2024-519639-40-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Stomach
Oesogastric junction
Oral cavity
Nasopharynx
Oropharynx
Hypopharynx
Larynx
Nasal cavities and sinuses
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
One-carbon Therapeutics AB
Phase 1 / Phase 2
Lung cancer
Stomach and esophageal cancer
Head and neck cancer
Cervical / Vulvar / Vaginal cancer
#NCT06747585
#2024-515459-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Esophagus
Cervical cancer
Required histologic sub types
Squamous NSCLC
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Alentis Therapeutics AG
Phase 1 / Phase 2
Bladder / Urinary Tract / Urethral cancer
#NCT07222488
#2025-520467-40-00
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
1
Required previous treatments at localized stage
Systemic Treatment-Naive
Surgery
Immunotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC
Phase 1 / Phase 2
Prostate cancer
#NCT06990880
#2025-521581-10
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Chemotherapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2
Lung cancer
#NCT06043817
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
HER2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2
Breast cancer
#NCT05768139
#2023-000442-41
Cohortes combinaison extension de dose cancer du sein RH+
Required HER2 statuses
HER2 Negative
HER2 Low
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Eli Lilly et compagnie